External validation of a heart failure risk score in patients with acute myeloid leukemia

Doukas, Peter; Cascino, Gregory J; Meng, Zhiying; Baldridge, Abigail S.; Kang, Yu Min; Scherrer‐Crosbie, Marielle; Akhter, Nausheen

doi:10.1080/10428194.2022.2140289

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pre-treatment assessment of GLS of patients with leukemia and lymphoma who receive anthracycline-based chemotherapy has been shown to have prognostic significance in several studies. 17,[24][25][26] There was also a statistically significant difference in baseline MV…”

Section: Discussionmentioning

confidence: 88%

“…The difference in cancer subtypes of patients enrolled in SUCCOUR and our study is relevant, as patients with hematologic malignancies likely represent a cohort with unique leukemia and lymphoma‐driven risk. Pre‐treatment assessment of GLS of patients with leukemia and lymphoma who receive anthracycline‐based chemotherapy has been shown to have prognostic significance in several studies 17,24–26 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T‐cell therapy

Patel,

Dalal,

Meng

et al. 2023

European J of Haematology

Self Cite

View full text Add to dashboard Cite

BackgroundCardiovascular events, including heart failure and arrhythmias, following chimeric antigen receptor (CAR) T‐cell therapy are increasingly recognized. Although global longitudinal strain (GLS) has demonstrated prognostic utility for other cancer therapy‐related cardiac dysfunction, less is known regarding the association of GLS with adverse cardiac events following CAR T‐cell therapy.ObjectivesTo determine the association of baseline GLS with adverse cardiovascular events in adults receiving CAR‐T cell therapy.MethodsPatients who had an echocardiogram within 6 months prior to receiving CAR T‐cell therapy were retrospectively identified. Clinical data and cardiac events were collected via chart review. Echocardiograms were analyzed offline for GLS, left ventricular ejection fraction, and Doppler parameters. Multivariable logistic regression was used to determine the association between adverse cardiovascular events and echocardiographic parameters.ResultsAmong 75 CAR T‐cell therapy patients (mean age 63.9, 34.7% female), nine patients (12%) experienced cardiac events (CEs) including cardiovascular death, new/worsening heart failure, and new/worsening arrhythmia within 1 year of treatment. In univariable models, higher baseline GLS (OR 0.78 [0.63, 0.96], p = .021) was associated with a lower risk of CE and higher baseline mitral E/e' (OR 1.40 [1.08, 1.81], p = .012) was associated with a higher risk of CE. After adjusting for age and LDH, higher baseline GLS (OR 0.65 [0.48–0.88], p = <.01) was associated with a lower risk of CE and higher baseline mitral E/e' (OR 1.56 [1.06, 2.29], p = .024) was associated with a higher risk of CE.ConclusionLower GLS and higher mitral E/e' on a baseline echocardiogram were associated with higher risk for CEs in patients receiving CAR T‐cell therapy.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%